JSAM
AMLX icon

J. Safra Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

J. Safra Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.24K Buy
377
+254
+207% +$3.57K ﹤0.01% 460
2025
Q4 		$1.49K Buy
+123
New +$1.67K ﹤0.01% 605

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

J. Safra Asset Management's AMLX Position: Q1 2026 in Review

J. Safra Asset Management increased its Amylyx Pharmaceuticals (AMLX) stake by 207% in Q1 2026, buying an estimated $3.57K and bringing the position to 377 shares worth $5.24K. The position accounts for ﹤0.01% of the portfolio, ranked #460.

J. Safra Asset Management first reported a position in AMLX in Q4 2025 and has held it in 2 quarters since. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • J. Safra Asset Management held 377 shares of Amylyx Pharmaceuticals worth $5.24K as of Q1 2026.
  • J. Safra Asset Management bought 254 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $3.57K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of J. Safra Asset Management's portfolio in Q1 2026, its #460 holding.
  • J. Safra Asset Management first reported a position in Amylyx Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on J. Safra Asset Management's 13F filing for Q1 2026, filed 4 May 2026.